Conference Presentation, Interview
Revolutionizing Cancer Treatment with Immunotherapy: Talks at GS Session Highlights
Goldman SachsGiovanni Caforio, Laurie Glimcher, Jill O'Donnell-Tormey, Dr. Giovanni Coforio, Dr. Lori Glimcher, Jamie
- Combination immunotherapies are expected to increase the percentage of patients responding to treatment by raising the tail of the response curve.
- The field is increasingly shifting toward immunotherapy to tailor treatment based on each patient's unique tumor characteristics.
- Chemotherapy is anticipated to retain a role for some patients in earlier lines of therapy or across additional tumor types as the field develops.
- Immuno-oncology evolution is projected to enable personalized treatment approaches for any patient.
- Multiple treatment modalities will continue to be utilized alongside immuno-oncology, which is emerging as a leading modality.
- Achieving broader success in immune responses is expected to be a prolonged process, though current trajectory is considered positive.